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Symptom lead times in lung and colorectal
cancers: what are the benefits of symptom-
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M Biswas1, A E Ades*,1 and W Hamilton2
1School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK and
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Background: Individuals with undiagnosed lung and colorectal cancers present with non-specific symptoms in primary care more
often than matched controls. Increased access to diagnostic services for patients with symptoms generates more early-stage
diagnoses, but the mechanisms for this are only partially understood.
Methods: We re-analysed a UK-based case–control study to estimate the Symptom Lead Time (SLT) distribution for a range of
potential symptom criteria for investigation. Symptom Lead Time is the time between symptoms caused by cancer and eventual
diagnosis, and is analogous to Lead Time in a screening programme. We also estimated the proportion of symptoms in lung and
colorectal cancer cases that are actually caused by the cancer.
Results: Mean Symptom Lead Times were between 4.1 and 6.0 months, with medians between 2.0 and 3.2 months. Symptom
Lead Time did not depend on stage at diagnosis, nor which criteria for investigation are adopted. Depending on the criteria, an
estimated 27–48% of symptoms in individuals with as yet undiagnosed lung cancer, and 12–32% with undiagnosed colorectal
cancer are not caused by the cancer.
Conclusions: In most cancer cases detected by a symptom-based programme, the symptoms are caused by cancer. These cases
have a short lead time and benefit relatively little. However, in a significant minority of cases cancer detection is serendipitous. This
group experiences the benefits of a standard screening programme, a substantial mean lead time and a higher probability of
early-stage diagnosis.
There has been increasing emphasis on the need for earlier
investigation of suspected cancer in primary care. In the 2 years
before diagnosis individuals with cancer present more frequently
in primary care than matched controls with non-specific but
suggestive symptoms. This has been reported for lung (Hamilton
et al, 2005; Hippisley-Cox and Coupland, 2011; Iyen-Omofoman
et al, 2013), colorectal (Hamilton, 2009), and ovarian cancers
(Friedman et al, 2005; Hamilton, 2009; Lim et al, 2012). Similar
findings have been published 1 year before diagnosis in
pancreatic, oesophago-gastric, bladder, renal, and uterine
cancers (Shephard et al, 2012, 2013; Stapley et al, 2012, 2013;
Walker et al, 2013). It has been concluded that earlier diagnosis
could be achieved by instituting explicit criteria for investigation
in primary care (National Institute for Health and Care
Excellence (NICE), 2005; Scottish Intercollegiate Guidelines
Network (SIGN), 2014). In the United Kingdom, the Be Clear
on Cancer campaign funded by the Department of Health has
been successful in urging individuals with particular symptoms
to attend their GP surgery (Cancer Research UK, 2014a;
Department of Health, 2012), and in selecting some of those
individuals for investigation.
However, these studies have not established how much earlier
diagnosis could be brought forward in patients presenting in
primary care, nor how many individuals currently diagnosed at a
*Correspondence: Professor AE Ades; E-mail: t.ades@bristol.ac.uk
Received 4 August 2014; revised 24 September 2014; accepted 4 November 2014
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
FULL PAPER
Keywords: Symptom lead time; Symptom-based diagnosis; lung cancer; colorectal cancer
British Journal of Cancer (2014) 00, 1–7 | doi: 10.1038/bjc.2014.597
www.bjcancer.com |DOI:10.1038/bjc.2014.597 1Advance Online Publication: 2 December 2014
late stage could be diagnosed at earlier stages, when better
treatment options are available.
The present study examines symptom-based investigation of
lung and colorectal cancers from two points of view. First, it
provides estimates of the Symptom Lead Time (SLT) distribution
for these cancers. The SLT is the distribution of times between the
presentation of symptoms caused by cancer in primary care and the
eventual diagnosis of cancer (Lim et al, 2012; Ades et al, 2014). The
SLT’s role in a symptom-based programme is exactly analogous to
that of the Lead Time in a standard screening programme. In an
earlier, more technical, paper we estimated the SLT for lung cancer
taking account of the fact that a proportion of diagnoses are
already the result of GPs referring patients for chest X-ray (CXR)
following presentation of symptoms in primary care. We showed
that this had little impact on SLT. In this paper, we present
analyses of SLT for a wide range of potential investigational
criteria, in both lung and colorectal cancers.
A second objective of this paper is to estimate the proportion of
cancers detected in a symptom-based programme in whom the
symptoms that trigger the diagnostic investigation are actually
caused by the cancer. This is a critical parameter, because cancers
diagnosed as a result of symptoms that are not caused by cancer are
being picked up serendipitously, by what is in effect by a random
screening programme. It is therefore important to establish not
only that those whose symptoms are caused by cancer enjoy a
substantial lead time, and are therefore likely to benefit from earlier
diagnosis, but also what proportion of all cancers detected by
symptom-based programmes are serendipitous, and what the
implications of this are for symptom-based investigative strategies.
In discussion, we examine the implications of our results for
recent proposals in the United Kingdom to lower thresholds and
widen access to diagnostic investigations for these and other
cancers.
MATERIALS AND METHODS
This paper presents re-analyses of data collected on 247 lung
cancer and 349 colorectal cancer cases diagnosed in Exeter
(England) between 1998 and 2002, with five controls per case
matched on age, sex, and GP practice (Hamilton et al, 2005;
Hamilton, 2009). GP attendances over the 2-year period before
cancer diagnosis were recorded, along with stage at diagnosis.
Previous multivariable analyses had found that the following seven
symptoms were associated with lung cancer: cough, dyspnoea,
chest pain, fatigue, loss of weight, loss of appetite, and haemoptysis;
and the following five with colorectal cancer: rectal bleeding,
abdominal pain, loss of weight, diarrhoea, and constipation
(Hamilton et al, 2005; Hamilton, 2009).
Sensitivity and specificity. We examined the sensitivity (propor-
tion of cases meeting the symptom definition over the 2-year
period), and specificity (proportion of controls meeting the
definition) of: each individual symptom; any single symptom;
any two symptoms occurring within 1 month, within 2, 3, 4, 5, and
6 months.
Among the potential symptom criteria with sensitivity over
40%, we picked out the following five for further study, as they
represented a wide range of sensitivity and specificity. For lung
these were (i) cough, (ii) any of the seven symptoms, (iii) any two
of the seven symptoms within 3 months (including repeat
presentations of the same symptom), (iv) any two different
symptoms within 3 months, and (v) chest pain. For colorectal
cancer: (i) rectal bleeding; (ii) any of the five symptoms; (iii) any
two symptoms within 6 months; (iv) any two different symptoms
within 6 months; and (v) abdominal pain. These criteria include
the most sensitive criterion (any symptom), the criteria with the
highest diagnostic odds ratio (DOR), the criteria with the highest
Youden Index, the most sensitive single symptom, and the most
specific single symptom.
Symptom incidence and SLT distribution. We identified the
number of times patients met the symptom definitions in each of
eight 3-month intervals for lung cancer, and twelve 2-month
intervals for colorectal cancer. For each diagnostic criterion, the
rate of symptom presentation in cases and controls during each
interval was estimated by Poisson regression. We interpreted the
difference in incidence between cases and controls in each interval
as the rate of symptoms caused by cancer. The SLT distribution is
the incidence of symptoms caused by cancer in each interval,
divided by the summed incidence of symptoms caused by cancer
over the 2 years.
The proportion of symptoms in cases due to cancer. The
incidence of symptoms caused by cancer, as defined above, divided
by the total incidence in cases represents the proportion of
symptoms in cases that are caused by cancer. We estimated this
over the 2-year study period. We also estimated the proportion of
symptoms caused by cancer that would be observed if a strategy of
investigation based on these criteria were adopted in practice. This
calculation takes into account the sojourn times of the cancers and
allows for the possibility that symptoms caused by cancer could
occur more than 2 years before diagnosis (see Discussion and
Supplementary Materials).
Estimation was performed by Bayesian Markov chain Monte
Carlo in WinBUGS (Lunn et al, 2000; Spiegelhalter et al, 2007).
Further details of the statistical methods have been published
previously (Ades et al, 2014).
RESULTS
Stage at diagnosis. Of the 247 lung cancer cases, the proportions
in stages 1, 2, 3, 4 and unknown/missing are 12.6%, 6.9%, 12.6%,
22.3% and 45.7%, respectively. Of the 349 colorectal cancer cases,
the proportions in Duke’s A, B, C, D and unknown/missing are
13.2%, 35.8%, 28.7%, 10% and 12.3%, respectively.
Sensitivity and specificity of symptom criteria. The sensitivity
and specificity of the different symptom criteria are shown in
Table 1, along with the Youden index (sensitivityþ specificity 1),
and DOR.
Symptom incidence. The overall incidence (% per year) of each of
the investigative criteria in cases and controls is shown in Table 2.
There are no systematic differences in symptom incidence between
stages.
SLT distribution. The SLT for the criteria with the highest DOR
is shown for each stage, and the same pattern is evident at all stages
(Figure 1). Figure 2 gives the SLT averaged over all stages for each
of the five lung and colorectal cancer investigative criteria. Despite
the different sensitivity and specificity of the criteria, and their
different incidence, the SLT distributions are virtually identical.
The mean SLTs are between 4.7 and 6.0 months for lung cancer
and between 4.1 and 5.0 months for colorectal cancer (Table 3).
Median SLTs are between 2.4 and 3.2 for lung cancer, and between
2.0 and 2.7 for colorectal cancer.
Proportion of symptoms caused by cancer. The proportion of
symptoms that are caused by cancer rises from between 12% and
38% to over 95% over the 2-year period (Figure 3). Averaged over
the 2-year period of observation, between 66% and 83% of the
occurrences of investigative criteria for lung cancer are due to lung
cancer, and between 79% and 94% for colorectal cancer. Assuming
a mean sojourn times of 4 years for both cancers (see
Supplementary Materials and Discussion), the proportions that
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would be observed in practice are between 52% and 73% (lung),
and between 68% and 88% (colorectal).
DISCUSSION
This study confirms results from much larger earlier studies
(Hamilton et al, 2005; Hamilton, 2009; Hippisley-Cox and
Coupland, 2011; Iyen-Omofoman et al, 2013), showing that lung
and colorectal cancer cases present a range of characteristic
symptoms in primary care at a substantially higher rate than
matched controls, in the 2 years before diagnosis. However, these
findings have previously been reported in the form of odds ratios
and predictive values. Our analysis of SLT provides additional
quantitative information about the lead time distribution that
might be achieved by various symptom-based investigation
programmes. Specifically, we found that in both cancers the
majority of the excess symptom presentation rate occurs in the last
3 months before diagnosis.
The choice of which symptom definitions are used as criteria for
imaging appears to make little difference: the same result is
obtained both for relatively sensitive but non-specific criteria, such
as ‘any symptom’, and for more specific criteria, such as rectal
bleeding for colorectal cancer. An important advantage of the
present study is the information on stage at diagnosis. Symptom
incidence (Table 2) and SLT results (Figure 1) show no relation-
ship with stage. This suggests that few cases currently diagnosed at
a late stage could be diagnosed at an earlier stage on the basis of
symptoms caused by cancer presenting in primary care.
In an earlier more technical (Ades et al, 2014) paper on lung
cancer, we explored the possibility that the short lead time was
Table 1. Sensitivity and specificity of the different symptom criteria
Investigative criteria Sensitivity % Specificity % Youden index (95% CI) DOR (95% CI)
Lung cancer
Two different symptoms in 3 months 74.1 83.0 57.1 (51–63) 14.0 (10–19)
Cough 64.8 70.5 35.3 (29–49) 4.4 (3.3–5.9)
Any symptoms 91.9 52.8 44.7 (40–49) 12.7 (8.0–20)
Any two symptoms in 3 months 80.6 76.8 57.4 (52–63) 13.8 (9.8–19)
Chest pain 56.3 84.5 40.7 (34–47) 4.9 (3.6–6.7)
Colorectal cancer
Any symptoms 86.2 73.2 59.5 (55–64) 17.2 (12–24)
Rectal bleeding 42.4 90.7 38.2 (33–44) 16.9 (12–23)
Any two symptoms in 6 months 60.2 89.4 49.6 (44–55) 12.7 (9.8–17)
Two different symptoms in 6 months 47.0 93.0 40.1 (35–46) 12.0 (9.1–16)
Abdominal pain 42.4 90.7 33.1 (28–38) 7.1 (5.5–9.3)
Abbreviations: CI¼ confidence interval; DOR¼diagnostic odds ratio.
Table 2. Overall incidence (% per year) of each of the investigative criteria in cases and controls
Investigative
criteria Cases Controls
Lung cancer
Stage I
(N¼31)
Stage II
(N¼17)
Stage III
(N¼31)
Stage IV
(N¼55)
Missing/
Unknown
(N¼113)
Stage I
(N¼155)
Stage II
(N¼85)
Stage III
(N¼155)
Stage IV
(N¼275)
Missing/
Unknown
(N¼565)
Over all
cases
(N¼247)
Over all
controls
(N¼1235)
Two different
symptoms in
3 months
55.0 65.3 60.0 60.0 70.8 15.8 14.1 11.3 10.9 12.8 64.7 12.7
Cough 56.4 62.4 63.2 69.0 66.4 26.4 22.4 25.8 22.7 22.9 65.0 23.6
Any symptoms 132.2 117.8 114.6 127.2 135.0 52.6 44.7 48.1 42.4 47.6 129.2 46.9
Any two
symptoms in
3 months
68.0 77.1 74.4 75.5 85.9 22.3 19.4 17.1 15.1 18.1 79.3 17.9
Chest pain 24.5 39.4 23.2 32.8 33.2 8.1 7.6 7.7 5.8 9.8 31.2 8.3
Investigative
criteria Cases Controls
Colorectal
cancer
Duke’s A
(N¼46)
Duke’s B
(N¼125)
Duke’s C
(N¼100)
Duke’s D
(N¼35)
Missing/
Unknown
(N¼43)
Duke’s A
(N¼230)
Duke’s B
(N¼624)
Duke’s C
(N¼500)
Duke’s D
(N¼175)
Missing/
Unknown
(N¼215)
Over all
cases
(N¼349)
Over all
controls
(N¼1744)
Any symptoms 87.0 85.2 80.0 95.7 79.1 19.1 18.2 17.9 20.6 18.1 84.3 18.5
Rectal bleeding 45.9 26.0 25.2 23.7 32.1 2.0 2.1 3.0 2.3 2.6 28.9 2.4
Any two
symptoms in
6 months
47.9 46.4 43.6 57.4 44.5 5.0 6.3 6.3 6.3 8.4 46.7 6.4
Two different
symptoms in
6 months
33.8 33.6 30.6 42.0 34.3 2.6 3.9 4.5 3.4 5.3 33.7 4.0
Abdominal pain 29.7 35.2 31.0 44.7 29.2 6.1 5.4 6.6 7.7 6.5 33.5 6.2
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partly the result of GP referral of patients with suggestive
symptoms for chest X-ray. However, when patients with a CXR
finding of ‘suspected lung cancer’ were excluded, the mean SLT
was only 1 month longer. Thus, the estimates of SLT presented
here may slightly underestimate the true SLT, but not to an extent
that impacts on conclusions. Similar findings have been reported
for ovarian cancer (Lim et al, 2012). As far as we know SLT for
symptoms presenting in primary care has not been reported in any
other cancers.
Potential limitations of our analysis should be recognised: the
sample was small and restricted to the Exeter area, and whether it
is representative of current practice can be questioned. However,
there have been few significant changes in policy and practice since
the data were collected in 1998–2002, and there no were special
organisational features that would have influenced speed or route
of diagnosis, although increasing use of Computed Tomography
(CT) scans may lead to earlier diagnoses. Although a proportion of
lung cancer cases were unstaged, these tend to be those with
advanced disease. If we assume that unstaged are all Stage IV, then
the stage distribution in the data matches that of the two UK
registries with the most complete data, 2004–2007 (Walters et al,
2013). Further, because stage appears to be unrelated to symptom
incidence and SLT, it is unlikely that this missing data would affect
conclusions.
Our main finding that median SLT is seldom more than 3
months suggests that most of those whose symptoms are caused by
cancer might benefit relatively little in terms of time from
symptom-based diagnosis. This does not necessarily mean that
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Figure 2. Symptom Lead Time distribution for five investigative criteria, lung and colorectal cancers. Shaded areas between the highest and
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Figure 1. Symptom Lead Time distribution for ‘Any two symptoms in 3 months’ in lung cancer cases by stage and ‘Any symptoms’ in colorectal
cases by stage.
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the wide adoption of symptom-based diagnostic testing in primary
care would have little effect on cancer outcomes. The avoidance of
emergency presentation is a clear potential benefit, let alone any
stage shift. However, it does raise questions about the rationale for
such a strategy. To clarify this issue, we estimated the proportion of
symptoms in cases whose symptoms were caused by cancer. For
lung cancer, over the 24-month period before diagnosis, between
17% and 34% of symptoms presented by cases were not caused by
the cancer, and between 6% and 21% for colorectal cancer. If these
cases were referred for diagnostic imaging then the detection of
cancer would be essentially serendipitous. Thus, individuals whose
cancers are detected by a symptom-based programme are drawn
from two distinct populations. Those whose symptoms were
caused by cancer will benefit by having a lower risk of emergency
admission, but, according to our SLT findings, might experience
only relatively minor benefit in terms of stage at diagnosis as the
programme offers a mean lead time of only 4–6 months.
The second group, whose cancer was detected serendipitously,
have been diagnosed by what is, in effect, a screen carried at a
random moment in time when they were asymptomatic with
respect to their cancer. Mean lead times for these cases can be
inferred from mean sojourn time estimates based on screening
trials with multiple rounds (Day and Walter, 1984; Duffy et al,
1995; Prevost et al, 1998). The mean sojourn time for lung cancer
is in the region of 4 years (Jang et al, 2013). For colorectal cancer a
range of estimates between 2 and 6 years have been published
(Prevost et al, 1998; Brenner et al, 2011; Zheng and Rutter, 2012)
with an average of B4 years. Depending on the shape of the
sojourn time distribution, the mean lead time from screening
(assuming a perfect test) is usually greater than half the mean
sojourn time, therefore about 2 years for both cancers. This is why
standard screening programmes result in much earlier stage at
diagnosis, better treatment options, and better cancer outcomes.
It has been implicitly assumed that symptom-based diagnosis
identifies cases whose symptoms are caused by their cancer, and
offers them diagnosis and treatment at an earlier stage. Instead, it
seems that the benefits of a symptom-based cancer investigation
strategy are experienced to a much higher extent than currently
acknowledged by the cases whose symptoms are not caused by
their cancer. It follows that the symptom-based programme that is
based on the most sensitive and specific symptoms, although
potentially more efficient in finding cancers, may offer the least
clinical benefit to the cases that are detected.
This interpretation focusses attention on the results in Tables 1
and 4. The sensitivity, specificity, and proportion of symptoms due
to cancer as estimated over the 2-year study period are not what we
would expect to observe in a randomly chosen 2-year period. This
is because the case–control design flatters the efficiency of the
programme by over-sampling symptoms from the last 2 years of
the sojourn time, when symptoms occur with a particularly high
frequency. Therefore, we need to extrapolate Figure 3 back over the
length of the sojourn time to obtain unbiased estimates. Assuming
sojourn times of 4 years for both lung and colorectal cancers, we
can derive projections for the proportion of symptoms caused by
cancer that would be seen in practice. The estimates in Table 4 are
conservative in that they allow for the possibility that cases present
symptoms at a higher rate than controls for up to 3 years before
diagnosis (see Supplementary materials for Materials and meth-
ods). For the symptom criteria with the highest DOR, the
proportion of cases whose symptoms are caused by cancer is
73% for lung and 68% for colorectal. Note that less specific criteria
have a higher rate of serendipitous detection: ‘cough’ would be
caused by lung cancer in only 55% of cases.
These conclusions explain why the results of symptom-based
programmes appear quite favourable, in spite of the low SLT. The
Be Clear on Cancer campaign (Cancer Research UK, 2014a) has
reported an increase in consultation rates (for persistent cough),
increased chest X-ray referrals, an increased number of lung cancer
diagnoses and an increased proportion of early stage diagnoses.
However, any expansion of diagnostic testing necessarily generates
Table 3. Estimated mean and median Symptom Lead Time
(SLT) in months for lung and colorectal cancers
Investigative criteria Mean SLT Median SLT
Lung cancer
Two different symptoms in 3 months 4.7 (4.0–5.5) 2.4 (2.0–2.8)
Cough 6.0 (4.9–7.1) 3.2 (2.6–5.1)
Any symptom 5.5 (4.8–6.3) 2.9 (2.6–3.9)
Any two symptoms in 3 months 4.9 (4.2–5.6) 2.6 (2.2–3.0)
Chest pain 5.5 (4.3–6.9) 2.5 (1.9–4.0)
Colorectal cancer
Any symptoms 4.9 (4.3–5.6) 2.6 (2.1–3.3)
Rectal bleeding 4.6 (3.8–5.5) 2.4 (1.9–3.4)
Any two symptoms in 6 months 4.4 (3.8–5.1) 2.2 (1.8–2.9)
Two different symptoms in 6 months 4.1 (3.4–4.8) 2.0 (1.7–2.7)
Abdominal pain 5.0 (4.1–5.9) 2.7 (2.0–4.1)
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Figure 3. Probability of symptoms in cancer cases being due to cancer over 2-year period before diagnosis. Shaded areas between the most
extreme upper and lower 95% credible intervals.
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more diagnoses, and therefore earlier diagnoses. Our findings
suggest that these results should not be over-interpreted.
A further expansion of the National Awareness and Early
Diagnosis Initiative (Cancer Research UK, 2014b) has been
recently announced, involving lowering thresholds for diagnosis
and increasing access to diagnostic services through the introduc-
tion of more routes to diagnosis, potentially including patient self-
referral.
Symptom-based cancer investigation offers relatively little to the
majority of patients with symptoms, those whose symptoms were
caused by cancer, while offering a fair likelihood of early-stage
diagnosis to those identified serendipitously. It offers nothing to
the proportion of cancer sufferers who do not present with
symptoms at all, or who present atypically. In addition, the general
population with symptoms who do not have cancer must still
suffer all the disadvantages of cancer screening programmes: false
positives will undergo unnecessary, anxiety-provoking and invasive
investigations; true positives are at risk of over-diagnosis leading to
unnecessary major surgery. The Be Clear on Cancer campaign
reported a 20% increase in diagnostic investigations for lung
cancer, and a 9% increase in cancers detected, but also a 32%
increase in urgent referrals for suspected lung cancer (Cancer
Research UK, 2014a).
At the same time, the various safeguards that we associate with a
planned screening programme, such as equal opportunity to
benefit, logistic efficiency, and a national quality control pro-
gramme, will not be available in a symptom-based strategy as
currently conceived. Indeed, NHS England is actively encouraging
local commissioning groups to adopt a service configuration of
their own choice to promote earlier diagnosis. Among the options
suggested are: a role for pharmacists in cancer referrals, lowering
thresholds for urgent referral, and patient self-referral. We would
urge that a rigorous examination of costs and benefits is carried
out, perhaps by the National Screening Committee, before
symptom-based investigation programmes are further expanded.
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